Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 5/2015

01.05.2015 | Article

The MAST® D68C test: an interesting tool for detecting extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

verfasst von: C. Nourrisson, R. N. Tan, C. Hennequin, L. Gibold, R. Bonnet, F. Robin

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The Mast® D68C test is a phenotypical test that allows the detection of extended-spectrum β-lactamase (ESBL) production, even in AmpC-producing Enterobacteriaceae. We assessed its detection accuracy against a large collection of 106 Enterobacteriaceae isolates producing a wide diversity of well-characterized β-lactamases (53 ESBL producers, 25 Amp. producers, seven AmpC and ESBL producers, five carbapenemase producers, three carbapenemase and ESBL producers, one AmpC, carbapenemase, and ESBL producer, three TEM-1 producers, three SHV-1 producers, three OXA-1 producers, and one hyperOXY producer, ATCC 35218, ATCC 25922 [a β-lactamase-negative control strain]). The results were compared with those of the double disk test and the Clinical and Laboratory Standards Institute (CLSI) confirmatory test for the detection of ESBL. The sensitivity was 90.6 % for the synergy test, 87.5 % for the CLSI method, and only 73.1 % for D68C, which, however, reached 92.1 % if the strains for which supplementary investigations were recommended and the complex mutant TEM (CMT)-producing strains were excluded versus 94.1 % and 88.2 % for the other methods. The specificity was 90.2 % for the synergy test and 100 % for the CLSI method and D68C. D68C was also efficient in detecting AmpC-overproducing strains (sensitivity = 97 %, specificity = 95.9 %): among the 74 strains belonging to natural AmpC-producing species, the sensitivity and specificity were 100 and 94.8 %, respectively. The Mast® D68C-test is a promising method that is easy to perform for the detection of current ESBLs and could also be useful for the detection of plasmid-encoded AmpC enzymes (sensitivity = 100 %).
Literatur
1.
Zurück zum Zitat Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14(4):933–951, table of contentsCrossRefPubMedCentralPubMed Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14(4):933–951, table of contentsCrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R (1987) Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother 20(3):323–334CrossRefPubMed Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R (1987) Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother 20(3):323–334CrossRefPubMed
5.
Zurück zum Zitat Naas T, Poirel L, Karim A, Nordmann P (1999) Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 176(2):411–419PubMed Naas T, Poirel L, Karim A, Nordmann P (1999) Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 176(2):411–419PubMed
6.
Zurück zum Zitat Nordmann P, Naas T (1994) Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother 38(1):104–114CrossRefPubMedCentralPubMed Nordmann P, Naas T (1994) Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother 38(1):104–114CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P (2000) Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 44(3):622–632CrossRefPubMedCentralPubMed Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P (2000) Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 44(3):622–632CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Robin F, Delmas J, Schweitzer C, Bonnet R (2008) Evaluation of the Vitek-2 extended-spectrum beta-lactamase test against non-duplicate strains of Enterobacteriaceae producing a broad diversity of well-characterised beta-lactamases. Clin Microbiol Infect 14(2):148–154CrossRefPubMed Robin F, Delmas J, Schweitzer C, Bonnet R (2008) Evaluation of the Vitek-2 extended-spectrum beta-lactamase test against non-duplicate strains of Enterobacteriaceae producing a broad diversity of well-characterised beta-lactamases. Clin Microbiol Infect 14(2):148–154CrossRefPubMed
9.
Zurück zum Zitat Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC (2013) Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 57(11):5426–5431CrossRefPubMedCentralPubMed Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC (2013) Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 57(11):5426–5431CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40(6):2153–2162CrossRefPubMedCentralPubMed Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40(6):2153–2162CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, González-López JJ, Lara N, Martínez-Martínez L, Oliver A, Aracil B, Oteo J, Pascual A, Rodríguez-Baño J, Zamorano L, Navarro F (2013) Prevalence and molecular epidemiology of acquired AmpC beta-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 32(2):253–259CrossRefPubMed Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, González-López JJ, Lara N, Martínez-Martínez L, Oliver A, Aracil B, Oteo J, Pascual A, Rodríguez-Baño J, Zamorano L, Navarro F (2013) Prevalence and molecular epidemiology of acquired AmpC beta-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 32(2):253–259CrossRefPubMed
13.
Zurück zum Zitat Comité de l’Antibiogramme de la Société Française de Microbiologie (2007) Communiqué 2007 Comité de l’Antibiogramme de la Société Française de Microbiologie (2007) Communiqué 2007
14.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2014) Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement update. CLSI document M100-S24. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2014) Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement update. CLSI document M100-S24. CLSI, Wayne, PA
15.
Zurück zum Zitat Beceiro A, Maharjan S, Gaulton T, Doumith M, Soares NC, Dhanji H, Warner M, Doyle M, Hickey M, Downie G, Bou G, Livermore DM, Woodford N (2011) False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother 66(9):2006–2010CrossRefPubMed Beceiro A, Maharjan S, Gaulton T, Doumith M, Soares NC, Dhanji H, Warner M, Doyle M, Hickey M, Downie G, Bou G, Livermore DM, Woodford N (2011) False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother 66(9):2006–2010CrossRefPubMed
16.
Zurück zum Zitat Poirel L, Mammeri H, Nordmann P (2004) TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes. Antimicrob Agents Chemother 48(12):4528–4531CrossRefPubMedCentralPubMed Poirel L, Mammeri H, Nordmann P (2004) TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes. Antimicrob Agents Chemother 48(12):4528–4531CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R (2006) CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection. Antimicrob Agents Chemother 50(7):2403–2408CrossRefPubMedCentralPubMed Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R (2006) CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection. Antimicrob Agents Chemother 50(7):2403–2408CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, Bonnet R (2007) Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Chemother 51(4):1304–1309CrossRefPubMedCentralPubMed Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, Bonnet R (2007) Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Chemother 51(4):1304–1309CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Ingram PR, Inglis TJ, Vanzetti TR, Henderson BA, Harnett GB, Murray RJ (2011) Comparison of methods for AmpC beta-lactamase detection in Enterobacteriaceae. J Med Microbiol 60(Pt 6):715–721CrossRefPubMed Ingram PR, Inglis TJ, Vanzetti TR, Henderson BA, Harnett GB, Murray RJ (2011) Comparison of methods for AmpC beta-lactamase detection in Enterobacteriaceae. J Med Microbiol 60(Pt 6):715–721CrossRefPubMed
20.
Zurück zum Zitat Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS (2001) An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1. J Antimicrob Chemother 48(5):627–630CrossRefPubMed Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS (2001) An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1. J Antimicrob Chemother 48(5):627–630CrossRefPubMed
21.
Zurück zum Zitat Giakkoupi P, Tzouvelekis LS, Tsakris A, Loukova V, Sofianou D, Tzelepi E (2000) IBC-1, a novel integron-associated class A beta-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob Agents Chemother 44(9):2247–2253CrossRefPubMedCentralPubMed Giakkoupi P, Tzouvelekis LS, Tsakris A, Loukova V, Sofianou D, Tzelepi E (2000) IBC-1, a novel integron-associated class A beta-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob Agents Chemother 44(9):2247–2253CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M (2012) Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum beta-lactamases (ESBL) in Enterobacteriaceae. Clin Microbiol Infect 18(12):1194–1204CrossRefPubMed Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M (2012) Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum beta-lactamases (ESBL) in Enterobacteriaceae. Clin Microbiol Infect 18(12):1194–1204CrossRefPubMed
23.
Zurück zum Zitat Oliver A, Weigel LM, Rasheed JK, McGowan JE Jr, Raney P, Tenover FC (2002) Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 46(12):3829–3836CrossRefPubMedCentralPubMed Oliver A, Weigel LM, Rasheed JK, McGowan JE Jr, Raney P, Tenover FC (2002) Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 46(12):3829–3836CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Peter-Getzlaff S, Polsfuss S, Poledica M, Hombach M, Giger J, Böttger EC, Zbinden R, Bloemberg GV (2011) Detection of AmpC beta-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J Clin Microbiol 49(8):2924–2932CrossRefPubMedCentralPubMed Peter-Getzlaff S, Polsfuss S, Poledica M, Hombach M, Giger J, Böttger EC, Zbinden R, Bloemberg GV (2011) Detection of AmpC beta-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J Clin Microbiol 49(8):2924–2932CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M (2011) Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. J Clin Microbiol 49(8):2798–2803CrossRefPubMedCentralPubMed Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M (2011) Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. J Clin Microbiol 49(8):2798–2803CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Sabia C, Gargiulo R, Sarti M (2012) Evaluation of a double synergy differential test (DSDT) for differential detection of ESBL and AmpC-type beta-lactamases in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. New Microbiol 35(2):221–225PubMed Sabia C, Gargiulo R, Sarti M (2012) Evaluation of a double synergy differential test (DSDT) for differential detection of ESBL and AmpC-type beta-lactamases in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. New Microbiol 35(2):221–225PubMed
Metadaten
Titel
The MAST® D68C test: an interesting tool for detecting extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae
verfasst von
C. Nourrisson
R. N. Tan
C. Hennequin
L. Gibold
R. Bonnet
F. Robin
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 5/2015
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2305-6

Weitere Artikel der Ausgabe 5/2015

European Journal of Clinical Microbiology & Infectious Diseases 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.